CNX Therapeutics Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Private

  • Employees
  • 70

Employees

  • Latest Deal Type
  • Fund - Cont Trans

  • Financing Rounds
  • 5

  • Investments
  • 6

CNX Therapeutics General Information

Description

Manufacturer of specialty pharmaceutical products intended to improve the lives of patients with neurological, psychiatric, and critical care conditions. The company licenses, commercializes, and distributes prescription medicines for central nervous system disorders, critical care, oncology, and hospital settings through strategic partnerships and pan-European distribution networks, enabling healthcare providers, hospitals, and pharmaceutical partners to improve patient access to essential medicines across global markets.

Contact Information

Formerly Known As
Sunovion Pharmaceuticals Europe
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • LABS House
  • 15-19 Bloomsbury Way
  • London WC1A 2TH
  • England, United Kingdom
+44 020
Primary Industry
Pharmaceuticals
Other Industries
Distributors (Healthcare)
Vertical(s)
Corporate Office
  • LABS House
  • 15-19 Bloomsbury Way
  • London WC1A 2TH
  • England, United Kingdom
+44 020

CNX Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CNX Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CNX Therapeutics‘s full profile, request access.

Request a free trial

CNX Therapeutics Patents

CNX Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4626411-A1 Cannabinoids for treating essential tremor in patients Pending 02-Dec-2022
US-20260199377-A1 Cannabinoids for treating essential tremor in patients Pending 02-Dec-2022
EP-4514339-A1 Treatment of spasticity and pain in renally-impaired patients Pending 27-Apr-2022
US-20250262228-A1 Treatment of spasticity and pain in renally-impaired patients Pending 27-Apr-2022
US-8771760-B2 Method for the treatment of constipation Inactive 27-Apr-2005 A61K31/658
To view CNX Therapeutics’s complete patent history, request access »

CNX Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CNX Therapeutics Investments (6)

CNX Therapeutics’s most recent deal was a Buyout/LBO with Sativex. The deal was made on 30-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sativex 30-Oct-2025 Buyout/LBO Drug Discovery
Eisai (Two Central Nervous System Products) 28-Mar-2024 Buyout/LBO Buildings and Property
Sanofi (Panacod Medicine in Sweden) 30-Nov-2023 Buyout/LBO Buildings and Property
Sanofi (Propavan) 30-Nov-2023 Buyout/LBO Buildings and Property
Clinigen (Portfolio of Established Medicines) 09-Aug-2023 Buyout/LBO Pharmaceuticals
You’re viewing 5 of 6 investments. Get the full list »

CNX Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Cnx Therapeutics Ireland Dublin, Ireland 2023
CNX Therapeutics Netherlands Amsterdam, Netherlands 2018

CNX Therapeutics FAQs

  • When was CNX Therapeutics founded?

    CNX Therapeutics was founded in 1997.

  • Where is CNX Therapeutics headquartered?

    CNX Therapeutics is headquartered in London, United Kingdom.

  • What is the size of CNX Therapeutics?

    CNX Therapeutics has 70 total employees.

  • What industry is CNX Therapeutics in?

    CNX Therapeutics’s primary industry is Pharmaceuticals.

  • Is CNX Therapeutics a private or public company?

    CNX Therapeutics is a Private company.

  • What is CNX Therapeutics’s current revenue?

    The current revenue for CNX Therapeutics is .

  • How much funding has CNX Therapeutics raised over time?

    CNX Therapeutics has raised $4.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process